FindTrial
Sign In

Study on the proteomic effects of Chuanhong Zhongfeng Capsule on patients with Acute Cerebral Infarction

Study on the proteomic effects of Chuanhong Zhongfeng Capsule on patients with Acute Cerebral Infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000506
Enrollment
Unknown
Registered
2025-03-11
Start date
2023-05-10
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute cerebral infarction

Interventions

Control group:basic treatment
experimental group:basic treatment+Chuanhong Zhongfeng Capsule

Sponsors

The Affiliated Hospital of Changchun University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for ischemic stroke in the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018. (2) Meet the diagnostic criteria for ischemic stroke in traditional Chinese medicine. (3) Within 2 weeks of acute onset of ischemic stroke. (4) 4= NIHSS score < 15. (5) Age 40-80 years old.

Exclusion criteria

Exclusion criteria: (1) Diagnosis of hemorrhage or other pathological brain diseases based on CT or MRI of the head; (2) Those with allergies allergies to the test drug or its related medicinal taste or ingredients; (3) Age80 years old; (4) Patients with severe liver and kidney impairment.

Design outcomes

Primary

MeasureTime frame
proteins;—

Countries

china

Contacts

Public ContactDing Ying-yue

The Affiliated Hospital of Changchun University of Traditional Chinese Medicine

13578883346@163.com13578883346

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026